Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; proactive health and wellness screening; and preimplantation embryo testing and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. It also operates Patient Insights Networks, a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, an end-to-end platform that is used for the collection, analysis, and management of patient family history information. Invitae Corporation serves patients, healthcare providers, and biopharma and advocacy partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNYSE:NVTA
Previous Symbol
CUSIPN/A
Phone415-374-7782
Debt
Debt-to-Equity Ratio0.29
Current Ratio3.90
Quick Ratio3.90
Price-To-Earnings
Trailing P/E Ratio-4.54
Forward P/E Ratio-6.08
P/E GrowthN/A
Sales & Book Value
Annual Sales$68.22 million
Price / Sales13.17
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.30 per share
Price / Book5.23
Profitability
EPS (Most Recent Fiscal Year)($2.65)
Net Income$-123,380,000.00
Net Margins-109.60%
Return on Equity-103.37%
Return on Assets-59.39%
Miscellaneous
Employees594
Outstanding Shares74,620,000
Market Cap$898.39 million
OptionableOptionable
InVitae (NYSE:NVTA) Frequently Asked Questions
What is InVitae's stock symbol?
InVitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."
How were InVitae's earnings last quarter?
InVitae Corp (NYSE:NVTA) posted its quarterly earnings data on Wednesday, November, 7th. The medical research company reported ($0.45) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.47) by $0.02. The medical research company had revenue of $37.37 million for the quarter, compared to the consensus estimate of $34.80 million. InVitae had a negative return on equity of 103.37% and a negative net margin of 109.60%. The business's revenue for the quarter was up 105.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.57) EPS. View InVitae's Earnings History.
When is InVitae's next earnings date?
What price target have analysts set for NVTA?
5 brokers have issued 12-month price targets for InVitae's shares. Their forecasts range from $10.00 to $17.00. On average, they anticipate InVitae's share price to reach $14.50 in the next twelve months. This suggests a possible upside of 20.4% from the stock's current price. View Analyst Price Targets for InVitae.
What is the consensus analysts' recommendation for InVitae?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InVitae in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for InVitae.
Has InVitae been receiving favorable news coverage?
Media headlines about NVTA stock have trended somewhat positive this week, according to InfoTrie. The research group ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. InVitae earned a coverage optimism score of 1.0 on InfoTrie's scale. They also assigned news coverage about the medical research company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.
Who are some of InVitae's key competitors?
Some companies that are related to InVitae include Guardant Health (GH), Genomic Health (GHDX), CareDx (CDNA), Natera (NTRA), RadNet (RDNT), Veracyte (VCYT), Celcuity (CELC), Enzo Biochem (ENZ), Miragen Therapeutics (MGEN), Psychemedics (PMD), PotNetwork (POTN), Fulgent Genetics (FLGT), Cancer Genetics (CGIX), First Choice Healthcare Solutions (FCHS) and CBA Florida (CBAI).
Who are InVitae's key executives?
InVitae's management team includes the folowing people:
- Dr. Randal W. Scott, Exec. Chairman (Age 60)
- Dr. Sean E. George, Co-Founder, Pres, CEO & Director (Age 44)
- Ms. Shelly D. Guyer, Chief Financial Officer (Age 58)
- Mr. Lee Bendekgey, Chief Operating Officer (Age 60)
- Ms. Patricia E. Dumond, Chief Accounting Officer & VP of Fin. (Age 53)
When did InVitae IPO?
(NVTA) raised $76 million in an initial public offering on Thursday, February 12th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan served as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.
Who are InVitae's major shareholders?
InVitae's stock is owned by a number of of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (13.28%), BlackRock Inc. (7.29%), Gilder Gagnon Howe & Co. LLC (5.96%), Vanguard Group Inc (3.87%), Vanguard Group Inc. (3.87%) and Perceptive Advisors LLC (2.49%). Company insiders that own InVitae stock include Bros Advisors Lp Baker, E Lee Bendekgey, Eric Aguiar, Katherine Stueland, Patty Dumond, Randal W Scott, Robert L Nussbaum, Sean E George, Shelly D Guyer and Thomas Brida. View Institutional Ownership Trends for InVitae.
Which institutional investors are selling InVitae stock?
NVTA stock was sold by a variety of institutional investors in the last quarter, including Daiwa SB Investments Ltd., Redmile Group LLC, Perceptive Advisors LLC, Blair William & Co. IL, Man Group plc, TIAA CREF Investment Management LLC, GSA Capital Partners LLP and Gamco Investors INC. ET AL. Company insiders that have sold InVitae company stock in the last year include E Lee Bendekgey, Eric Aguiar, Katherine Stueland, Patty Dumond, Robert L Nussbaum, Sean E George, Shelly D Guyer and Thomas Brida. View Insider Buying and Selling for InVitae.
Which institutional investors are buying InVitae stock?
NVTA stock was purchased by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, Teachers Advisors LLC, ARK Investment Management LLC, Vanguard Group Inc, Vanguard Group Inc., Allianz Asset Management GmbH, Fuller & Thaler Asset Management Inc. and Great Lakes Advisors LLC. Company insiders that have bought InVitae stock in the last two years include Bros Advisors Lp Baker and Randal W Scott. View Insider Buying and Selling for InVitae.
How do I buy shares of InVitae?
Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is InVitae's stock price today?
One share of NVTA stock can currently be purchased for approximately $12.04.
How big of a company is InVitae?
InVitae has a market capitalization of $898.39 million and generates $68.22 million in revenue each year. The medical research company earns $-123,380,000.00 in net income (profit) each year or ($2.65) on an earnings per share basis. InVitae employs 594 workers across the globe.
What is InVitae's official website?
How can I contact InVitae?
InVitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at 415-374-7782 or via email at [email protected]
MarketBeat Community Rating for InVitae (NYSE NVTA)
MarketBeat's community ratings are surveys of what our community members think about InVitae and other stocks. Vote "Outperform" if you believe NVTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
